Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for the treatment of erectile dysfunction using fispemifene

a technology of erectile dysfunction and fispemifene, which is applied in the field of treatment of erectile dysfunction using fispemifene, can solve problems such as insufficient responsiveness, and achieve the effect of improving erectile function

Inactive Publication Date: 2010-10-14
QUATRX PHARMA
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The invention is a method of treating erectile dysfunction by administering fispemifene to individuals with low testosterone levels. The treatment can be used alone or in combination with other drugs such as PDE-5 inhibitors or selective estrogen receptor modulators. The method can also be used for individuals with chronic obstructive pulmonary disease, HIV infection, or metabolic syndrome. The technical effect of the invention is to improve erectile functioning in individuals with low testosterone levels."

Problems solved by technology

This may be an individual who has been determined to be insufficiently responsive to treatment with a PDE-5 inhibitor alone.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the treatment of erectile dysfunction using fispemifene
  • Methods for the treatment of erectile dysfunction using fispemifene
  • Methods for the treatment of erectile dysfunction using fispemifene

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0052]Fispemifene has been studied in two phase I studies in humans—in a single dose and a repeated dose study. Effect of fispemifene on hormone levels was one main focus of the repeated dose study. The phase I repeated dose study (number 101-50202) was a randomized, double-blind, placebo-controlled 28-day dose-escalation study performed in 31 healthy, elderly men, aged 50-68 years. The main objective of the study was to investigate the tolerability, safety and pharmacokinetics of fispemifene after repeated oral doses, but the study focused also on the effects of fispemifene on serum free and total testosterone, estradiol, and other relevant hormones. The fispemifene doses 10, 30, 100 and 300 mg per day and placebo were administered once every morning as capsules containing 10 mg or 100 mg of fispemifene, or placebo. The dose was escalated to the next higher dose level, if the previous dose had been safe and well tolerated evaluated by the laboratory safety determinations and ultras...

example 2

[0059]This is a prophetic example. Subjects would be selected from men, all over twenty years of age, unresponsive to PDE-5 inhibitor treatment as demonstrated by responses on the IIEF for a 28 day lead-in period, having morning total testosterone level less than or equal to 400 ng / dL. Half of the subjects would be assigned to the fispemifene treatment group (fispemifene plus sildenafil) and half will be assigned to the placebo control group (sildenafil without fispemifene). Subjects would self administer fispemifene once daily in the morning after breakfast for 8 weeks. Subjects would take sildenafil 100 mg on an as needed basis when sexual activity is anticipated.

[0060]The following observations would be expected: increases in total testosterone levels from baseline to week 4 to week 8; improvement in IIEF erectile function domain score from baseline to week 4 to week 8; improvement in other IIEF domain scores from baseline to week 4 to week 8.

example 3

[0061]A randomized, double-blind, placebo controlled, parallel-group study of once-daily doses of fispemifene (100, 200, and 300 mg / day) given for 4 weeks was conducted in a population of hypogonadal men. Subjects were required to meet all of the following inclusion criteria at screening and prior to randomization to be eligible for the study:

[0062]1. The subject had signed a written informed consent to participate in the study and had agreed to follow dosing instructions and complete all required study visits;

[0063]2. The subject was a male >40 years of age at the time of randomization.

[0064]3. The subject had a screening total testosterone level and a confirmatory baseline total testosterone level <350 ng / dL. Testosterone levels were determined from early morning (0700 h to 0900 h) specimens; and

[0065]4. The subject had a serum LH level of 1.7-15.0 IU / L and an FSH level of 1.5-15.0 IU / L at the screening visit.

[0066]Subjects were excluded from the study if they had an elevated seru...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
time pointsaaaaaaaaaa
timeaaaaaaaaaa
equilibrium dialysisaaaaaaaaaa
Login to View More

Abstract

A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of U.S. patent application Ser. No. 12 / 138,560, filed Jun. 13, 2008, which application claims the benefit of U.S. Provisional Application No. 60 / 943,706, filed Jun. 13, 2007. The disclosures of the priority applications are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]The invention relates to a method for treatment of erectile dysfunction (“ED”) using fispemifene, including: the use of fispemifene as a primary treatment for ED in individuals with low testosterone; the use of fispemifene in combination with another ED drug (such as type V phosphodiesterase (“PDE-5”) inhibitors) as combination therapy; and the use of fispemifene for the treatment of ED in individuals who have failed treatment with a PDE-5 inhibitor. The invention also relates to the use of selective estrogen receptor modulators (SERMs) including, but not limited to, fispemifene, clomifene, enclomifene, osp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/497A61P15/10
CPCA61K9/00A61K31/075A61K31/085A61K31/519A61K31/496A61K31/4985A61K31/53A61K31/135A61P15/00A61P15/10
Inventor ZERBE, ROBERT L.BRIDGES, ALEXANDERLAMMINTAUSTA, RISTOHANLEY, ROCHELLEDOMBEY, STUART
Owner QUATRX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com